Fig. 7.
Fig. 7. Activation of NF-κB in primary ATL cells. (A) Nuclear extracts (5 μg) from PBMC from patients with ATL or from healthy subjects (normal) were assessed for activation of NF-κB by EMSA. The right panel represents a lighter exposure of patients 2, 5, 6, and 7. (B) Nuclear extracts from patients with ATL or from healthy subjects (normal) were analyzed for protein binding to the octamer consensus sequence by EMSA. (C) Nuclear extracts from patient 3 sample were coincubated with 100-fold excess of unlabeled oligonucleotides and assessed in parallel. (D) Nuclear extracts were preincubated with NF-κB subunit-specific antibody, as indicated above each lane, before the addition of radiolabeled probe (as in Fig 6).

Activation of NF-κB in primary ATL cells. (A) Nuclear extracts (5 μg) from PBMC from patients with ATL or from healthy subjects (normal) were assessed for activation of NF-κB by EMSA. The right panel represents a lighter exposure of patients 2, 5, 6, and 7. (B) Nuclear extracts from patients with ATL or from healthy subjects (normal) were analyzed for protein binding to the octamer consensus sequence by EMSA. (C) Nuclear extracts from patient 3 sample were coincubated with 100-fold excess of unlabeled oligonucleotides and assessed in parallel. (D) Nuclear extracts were preincubated with NF-κB subunit-specific antibody, as indicated above each lane, before the addition of radiolabeled probe (as in Fig 6).

Close Modal

or Create an Account

Close Modal
Close Modal